DermTech to Announce First Quarter Financial Results on May 13, 2021
April 29 2021 - 4:01PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in
precision dermatology enabled by a non-invasive skin genomics
platform, announced today it plans to release its first quarter
2021 financial results after the market closes on Thursday, May 13,
2021. In conjunction with such release, the Company plans to host a
conference call and webcast that day at 1:30 p.m. Pacific time /
4:30 p.m. Eastern time to discuss its financial results and recent
highlights.
Interested parties may access the live call via telephone by
dialing (844) 467-7114 for domestic callers or (409) 231-2086 for
international callers, using conference ID: 1463529. The live
webinar for the call may be accessed by visiting the Events section
of the Company's website at investors.DermTech.com. A replay of the
webinar will be available on the Company’s website shortly after
the conclusion of the call.
About DermTech:
DermTech is the leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by our non-invasive skin genomics platform. DermTech’s mission is
to transform dermatology with our non-invasive skin genomics
platform, to democratize access to high quality dermatology care,
and to improve the lives of millions. DermTech provides genomic
analysis of skin samples collected non-invasively using an adhesive
patch rather than a scalpel. DermTech markets and develops products
that facilitate the early detection of skin cancers, and is
developing products that assess inflammatory diseases and customize
drug treatments. For additional information on DermTech, please
visit DermTech’s investor relations site at: www.DermTech.com.
Forward-Looking Statements:
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations with respect to: the performance, patient
benefits, cost-effectiveness and commercialization of DermTech’s
products and the market opportunity therefor. These forward-looking
statements involve significant risks and uncertainties that could
cause the actual results to differ materially from the expected
results. Most of these factors are outside of the control of
DermTech and are difficult to predict. Factors that may cause such
differences include, but are not limited to: (1) the outcome of any
legal proceedings that may be instituted against DermTech; (2)
DermTech’s ability to obtain additional funding to develop and
market its products; (3) the existence of favorable or unfavorable
clinical guidelines for DermTech’s tests; (4) the reimbursement of
DermTech’s tests by Medicare and private payors; (5) the ability of
patients or healthcare providers to obtain coverage of or
sufficient reimbursement for DermTech’s products; (6) DermTech’s
ability to grow, manage growth and retain its key employees; (7)
changes in applicable laws or regulations; (8) the market adoption
and demand for DermTech’s products and services together with the
possibility that DermTech may be adversely affected by other
economic, business, and/or competitive factors; and (9) other risks
and uncertainties included in (x) the “Risk Factors” section of the
most recent Annual Report on Form 10‑K filed by DermTech with the
Securities and Exchange Commission (the “SEC”), and (y) other
documents filed or to be filed by DermTech with the SEC. DermTech
cautions that the foregoing list of factors is not exclusive. You
should not place undue reliance upon any forward-looking
statements, which speak only as of the date made. DermTech does not
undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210429005230/en/
DermTech Sarah Dion sdion@dermtech.com 858.450.4222
Westwicke Partners IR Caroline Corner, PhD
caroline.corner@westwicke.com 415.202.5678
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2024 to May 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From May 2023 to May 2024